MeiraGTx secures FDA breakthrough designation for Xerostomia therapy
MeiraGTx Holdings (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today reported financial results for the full year ended December 31, 2025, and provided a comprehensive update on its late-stage clinical pipeline.










